about
S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE)The HMGB1-RAGE Inflammatory Pathway: Implications for Brain Injury-Induced Pulmonary DysfunctionA multicellular signal transduction network of AGE/RAGE signalingRegulation of RAGE splicing by hnRNP A1 and Tra2β-1 and its potential role in AD pathogenesisTranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell ProliferationThe receptor for advanced glycation end products (RAGE) and the lung.Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic ratsCo-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.S100P: a novel therapeutic target for cancer.Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation.RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer.High mobility group box 1 antagonist limits metastatic seeding in the lungs via reduction of cell-cell adhesion.Concurrent alterations of RAGE, RECK, and MMP9 protein expression are relevant to Epstein-Barr virus infection, metastasis, and survival in nasopharyngeal carcinoma.Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging.Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas.Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signalingThe S100B protein in biological fluids: more than a lifelong biomarker of brain distress.RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLCEvidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.Oligomerization interface of RAGE receptor revealed by MS-monitored hydrogen deuterium exchangeAlternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function.RAGE signaling significantly impacts tumorigenesis and hepatic tumor growth in murine models of colorectal carcinoma.Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events.S100A8 and S100A9: new insights into their roles in malignancy.Dicarbonyl Induced Structural Perturbations Make Histone H1 Highly Immunogenic and Generate an Auto-Immune Response in CancerAGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradationDown-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways.The Role of receptor for Advanced Glycation End Products (RAGE) in the proliferation of hepatocellular carcinomaThe receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.Lung adenocarcinoma expressing receptor for advanced glycation end-products with primary systemic AL amyloidosis: a case report and literature review.Identification of the interplay between SOX9 and S100P in the metastasis and invasion of colon carcinoma.Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation.Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma.Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ protein NMR spectroscopy.Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines.sRAGE induces human monocyte survival and differentiationRAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.The receptor RAGE: Bridging inflammation and cancerEndogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.
P2860
Q21135467-ABC63940-4E27-4E1D-BE68-8D3783099098Q28085089-AC8742F7-4B0A-4E74-A45C-B41D4E7F83C0Q28704994-70E683B4-F544-4640-88EC-833677CEE97AQ28910474-65EA573D-6F94-4BDD-B159-06479CDD95A0Q31102154-51647D3F-68D0-406A-9296-7386E35478E1Q33633330-8BB5969A-42C3-4659-A483-685BB9E32BD3Q33654871-B7CEF1C4-AB59-4538-929B-1DAAF5EF7724Q33693936-2503A538-18D8-4A2C-8093-2BB6334F848BQ33699305-13EA7B4E-4D25-436A-917E-D6402CCE27E9Q33710953-358A848E-2058-4FE5-9739-81BF35296B70Q33726461-FBE47484-6B86-4585-A858-3A386713F41DQ33779216-116F59AE-EF53-491D-B2AE-A28F51C3CE3FQ33898573-BAEE5269-9D77-49C0-9802-1D6BEDCB9520Q33932673-054F70B2-8F20-4344-9EBC-DD14671DD690Q34005255-96812711-F5D7-47CD-B273-12FCD2CFCB35Q34019875-27DD048A-B452-4FD1-8CCD-0807CD31BDCFQ34056610-66D0DE65-1C25-4A2A-AE9D-105347B97C93Q34238722-0FCA4B3E-6137-4F61-8456-45878B73B296Q34446751-BD723C2A-454B-4359-BD3A-7252270A1B5EQ34987953-5B99A2AC-3B32-455E-8BB3-5678A79ECC3FQ35009387-B700E336-38C2-4607-B36A-5DB31F77A4A0Q35048039-D6020B5B-A4C5-4379-A759-B6F367CDC37EQ35102969-094A4813-69E8-4994-9DD9-610932379A3DQ35170154-4FD052C9-86E0-4180-8363-BDFAB5B5E187Q35649454-48618F89-BFEB-4705-969C-CA8C2926B21BQ35759066-39192C6D-7E26-4F8C-AC8A-7829225524C6Q35835242-75BBDAF3-6656-439A-BB73-AC9E35B92D17Q35971858-EF7F86F8-8E2D-45C8-8C77-F0A03F789EEBQ36057340-36A31D8D-B2E9-4721-91B9-EFA0A22F6949Q36157988-ED41C304-0D54-4B9F-9C66-90CC917AE207Q36240992-A169FDF0-C9F6-4D37-98DE-B28718E0A183Q36299781-2DCD7007-3296-4DAF-A2EA-84A7322450EBQ36414193-82619275-0FFB-4504-95B1-C0DD995E3F77Q36429573-81A74C2F-539E-4672-8623-C2DCFFB5D488Q36796758-A40529FE-259E-4B9F-BA40-676A2C107F8CQ36820542-81727D83-1EB3-4618-8DC9-9748D3C0F8D6Q36900801-02E3181A-EAFA-4B7A-B403-26F8EAC6BD03Q37152947-39D12252-CB9D-4B68-95BE-5FF9F3E64ED6Q37212720-E9C31CF1-2CC5-41B2-BA18-44701EE17B34Q37229916-3B15EB2A-2787-4469-9CAE-60BAA8AD84BC
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RAGE and RAGE ligands in cancer.
@en
RAGE and RAGE ligands in cancer.
@nl
type
label
RAGE and RAGE ligands in cancer.
@en
RAGE and RAGE ligands in cancer.
@nl
prefLabel
RAGE and RAGE ligands in cancer.
@en
RAGE and RAGE ligands in cancer.
@nl
P2093
P1476
RAGE and RAGE ligands in cancer.
@en
P2093
Craig D Logsdon
Maren K Fuentes
Thiruvengadam Arumugam
P304
P356
10.2174/156652407783220697
P577
2007-12-01T00:00:00Z